Evidence map›Paper›PMID 33197400›Full record

ArticleChest2021

Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States.

Raymond U Osarogiagbon, Helmneh M Sineshaw, Chun Chieh Lin, Ahmedin Jemal

Open access · greenAbstract read
In one paragraph

Article in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Surgeon Quality and Patient Survival After Resection for Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  8. Institution-Level Evolution of Lung Cancer Resection Quality With Implementation of a Lymph Node Specimen Collection Kit.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023
    Article
  9. Article
  10. Outcomes After Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021
    Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Raymond U OsarogiagbonThoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN. Electronic address: rosarogi@bmhcc.org.
Helmneh M SineshawSurveillance and Health Services Research Program, American Cancer Society, Atlanta, GA.
Chun Chieh LinSurveillance and Health Services Research Program, American Cancer Society, Atlanta, GA.
Ahmedin JemalSurveillance and Health Services Research Program, American Cancer Society, Atlanta, GA.
American Cancer Society · USRegional Cancer Center · US

Funding

Improving pathologic nodal staging of resected lung cancerR01CA172253 · NCI · UNIVERSITY OF MEMPHIS · PI OSAROGIAGBON, RAYMOND U · 2013 to 2022
$4.8M
NCI NIH HHS R01 CA172253
6 · The paper itself

Abstract

backgroundInstitutional-level disparities in non-small cell lung cancer (NSCLC) survival may be driven by reversible differences in care-delivery processes. We quantified the impact of differences in readily identifiable quality metrics on long-term survival disparities in resected NSCLC. RESEARCH QUESTION: How do reversible differences in oncologic quality of care contribute to institutional-level disparities in early-stage NSCLC survival? STUDY DESIGN AND

methodsWe retrospectively analyzed patients in the National Cancer Data Base who underwent NSCLC resection from 2004 through 2015 within institutions categorized as Community, Comprehensive Community, Integrated Network, Academic, and National Cancer Institute (NCI)-Designated Cancer Programs. We estimated percentages and adjusted ORs for six potentially avoidable poor-quality markers: incomplete resection, nonexamination of lymph nodes, nonanatomic resection, non-evidence-based use of adjuvant chemotherapy, non-evidence-based use of adjuvant radiation therapy, and 60-day postoperative mortality. By sequentially eliminating patients with poor-quality markers and calculating adjusted hazard ratios, we quantified their overall survival impact.

resultsOf 169,775 patients, 7%, 46%, 10%, 24%, and 12% underwent surgery at Community, Comprehensive Community, Integrated Network, Academic, and NCI-Designated Cancer Programs, with 5-year overall survival rates of 52%, 56%, 58%, 60% and 66%, respectively. After the sequential elimination process, using NCI-Designated Cancer Centers as a reference, the adjusted hazard ratio for 5-year overall survival changed from 1.47 (95% CI, 1.41-1.53), 1.29 (95% CI, 1.25-1.33), 1.18 (95% CI, 1.14-1.23), and 1.20 (95% CI, 1.16-1.24) for Community, Comprehensive Community, Integrated Networks, and Academic Cancer Programs to 1.35 (95% CI, 1.28-1.42), 1.22 (95% CI, 1.17-1.26), 1.16 (95% CI, 1.11-1.22), and 1.17 (95% CI, 1.12-1.21), respectively (P < .001 for all comparisons with NCI-designated programs). Differences in quality of surgical resection and postoperative care accounted for 11% to 26% of the interinstitutional survival disparities.

interpretationTargeting six readily identified poor-quality markers narrowed, but did not eliminate, institutional survival disparities. The greatest impact was in community programs. Residual factors driving persistent institution-level long-term NSCLC survival disparities must be characterized to eliminate them.

Indexed as

Outcome and Process Assessment, Health CareQuality Indicators, Health CareAdolescentAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDatabases, FactualFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesUnited Stateshealth-care disparitieslung cancer surgerynon-small cell lung cancerquality improvement

Identifiers

PMID33197400
PMCPMC8147100
OpenAlexW3103108059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.